We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current CTXR market cap is 116.11M. The company's latest EPS is USD -0.2118 and P/E is -3.40.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 3.59M | 0 |
| Operating Income | -13.45M | -7.25M | -10.69M | -5.09M | -10.13M |
| Net Income | -13.89M | -3.59M | -10.24M | -8.77M | -11.1M |
| Year End 30 September 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -15.6M | -17.71M | -23.53M | -39.22M | -36.73M |
| Net Income | -15.56M | -17.55M | -23.05M | -39.54M | -33.69M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 114M | 111.71M | 104.24M | 110.41M | 103.61M |
| Total Liabilities | 10.57M | 10.67M | 12.43M | 12.11M | 12.18M |
| Total Equity | 103.43M | 101.03M | 91.81M | 98.3M | 91.43M |
| Year End 30 September 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 28.99M | 43.77M | 142.43M | 114M | 103.61M |
| Total Liabilities | 4.61M | 10.1M | 9.65M | 10.57M | 12.18M |
| Total Equity | 24.38M | 33.67M | 132.78M | 103.43M | 91.43M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -28.36M | -4.83M | -12.68M | -22.26M | -29.06M |
| Investing | N/A | N/A | N/A | N/A | N/A |
| Financing | N/A | N/A | 31k | 13.83M | 13.83M |
| Year End 30 September 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -12.44M | -16.93M | -24.25M | -28.36M | -29.06M |
| Investing | N/A | -2k | -40.01M | N/A | N/A |
| Financing | 11.15M | 22.9M | 120.47M | N/A | 13.83M |
| Market Cap | 116.11M |
| Price to Earnings Ratio | -3.40 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 4.33 |
| Price to Book Ratio | 1.25 |
| Dividend Yield | - |
| Shares Outstanding | 159.09M |
| Average Volume (1 week) | 2.14M |
| Average Volume (1 Month) | 1.28M |
| 52 Week Change | -53.81% |
| 52 Week High | 1.6189 |
| 52 Week Low | 0.60 |
| Spread (Intraday) | 0.01 (1.34%) |
| Company Name | Citius Pharmaceuticals Inc |
| Address |
112 north curry street carson city, nevada 89703 |
| Website | https://www.citiuspharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
